A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge.
Eight monkeys were immunized at 0, 4, 9, and 18 weeks with a total of 2 mg of formalin inactivated SIVmac vaccine with Ribi adjuvant. Two weeks after the last booster four immunized monkeys and two controls were challenged with 10 MID50 of live homologous virus SIVmac, and the remaining four vaccinated animals along with two controls were challenged with the heterologous SIVsm strain. All eight vaccinated monkeys resisted the virus challenge, whereas all controls became infected. Three months after the first challenge the monkeys were rechallenged with the same virus strain, without further boosting. Two of four vaccinated monkeys were still resistant to the homologous SIV strain, and three of four monkeys were resistant to the heterologous SIVsm strain. This study demonstrates vaccine induced cross-protection between SIV strains.
Putkonen
P
P
Department of Immunology, National Bacteriological Laboratory, Stockholm, Sweden.
Thorstensson
R
R
Cranage
M
M
Nilsson
C
C
Ghavamzadeh
L
L
Albert
J
J
Greenaway
P
P
Biberfeld
G
G
D000276:Adjuvants, Immunologic; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D016131:Lymphocyte Subsets; D008252:Macaca fascicularis; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D014611:Vaccination / Q000662:veterinary; D015164:Vaccines, Inactivated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014765:Viral Vaccines